Abstract:Abstract The approval of an increasing number of molecularly targeted therapies in cancer creates an opportunity to contemplate combinations of such agents. This is particularly important because single agents typically exhibit limited activity and very often drug resistance in clinic. A current challenge is to identify appropriate rational combinations that combine distinct mechanisms to elicit maximal anti-tumor activity and to overcome drug resistance. Tivozanib (formerly AV-951 or KRN951) is a small molecule VEGFR inhibitor that has been shown to be active in a phase 2 clinical trial in RCC. Tivozanib inhibits VEGFR 1, 2 and 3 activity at picomolar concentrations (IC50 of 0.21, 0.16 and 0.24 nM respectively), Rapamycin targets mTOR, a protein involved in integrating nutrient availability with cellular functions, including proliferation. mTOR is also known to promote hypoxia inducible factor (HIF1) activity, which in turn drives angiogenesis, such that in some settings, rapamycin is thought to elicit anti-tumor activity through an anti-angiogenic mechanism. We studied the activity of tivozanib and rapamycin as single agents and in combination in a genetically engineered HER2 driven breast adenocarcinoma model where multiple primary tumors have been expended in vivo for mechanisms of response and drug resistance biomarker exploration. These tumors exhibit significant variation in response to tivozanib. In one group of tumors, tivozanib as a single agent induced complete tumor growth inhibition persisting for at least 6 weeks. Rapamycin at a clinically relevant dose also induced complete tumor growth inhibition. However, histological analysis after short (5 days) or longer (35 days) term treatment revealed distinct mechanisms of action, i.e., anti-VEGF for tivozanib but direct antiproliferation for rapamycin. Combination of tivozanib and rapamycin resulted in substantially greater overall tumor reduction with evidence of both anti-angiogenic and anti-proliferation activities. Importantly, after 6 weeks of treatment, regions of drug resistance start to emerge in either rapamycin or tivozanib monotherapy tumors. However no evidence of drug resistance was observed with the tivozanib/rapamycin combination. To further explore the combination activity in resistant tumors, we established a resistant sub-line by long term tivozanib treatment. Both tivozanib and rapamycin as single agents resulted in only partial tumor growth inhibition. The combination treatment induced complete growth inhibition with evidence of both angiogenesis inhibition and direct antitumor effect. The distinct mechanisms of action of these two agents, along with the apparent suppression of drug resistance suggest that tivozanib and mTOR inhibitors may represent an attractive rational combination treatment for solid malignancies. At this point, an on-going phase 1B trial in RCC has shown that tivozanib can be combined with temsirolimus at full doses of both agents. An all oral combination of tivozanib and everolimus, an oral mTOR inhibitor, is also being developed for RCC and other tumors. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B143.

Application of mTOR inhibitor in preparing medicine for treating venation melanoma

Application of pan-HDAC inhibitor to preparation of drug used for treating uveal melanoma

Application of EZH2 (enhancer of zeste homolog 2) inhibitor compounds in preparation of drugs for treating eye melanoma

Evaluation of the antitumor effects of PP242 in a colon cancer xenograft mouse model using comprehensive metabolomics and lipidomics

Furthering the Design and the Discovery of Small Molecule ATP-competitive Mtor Inhibitors As an Effective Cancer Treatment

The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model.

Abstract B143: Distinct Antitumor Mechanisms of VEGFR Inhibitor Tivozanib (AV-951) and Mtor Inhibitor Rapamycin Support Rational Combination for Solid Tumors to Overcome Drug Resistance

Pp242 Suppresses Cell Proliferation, Metastasis, and Angiogenesis of Gastric Cancer Through Inhibition of the Pi3k/Akt/Mtor Pathway

Abstract B145: Highly Selective Pyrazolopyrimidine Mtor Inhibitors with Profound in Vivo Antitumor Activity

Application of CTCF snare protein in preparation of anti-uveal melanoma medicine

Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry

Transdermal treatment for malignant melanoma by aptamer-modified tetrahedral framework nucleic acid delivery of vemurafenib

Strongly ROS-Correlated, Time-Dependent, and Selective Antiproliferative Effects of Synthesized Nano Vesicles on BRAF Mutant Melanoma Cells and Their Hyaluronic Acid-Based Hydrogel Formulation

A Polymer–lipid Membrane Artificial Cell Nanocarrier Containing Enzyme–oxygen Biotherapeutic Inhibits the Growth of B16F10 Melanoma in 3D Culture and in a Mouse Model

Nanosecond Pulsed Electric Fields Enhance the Anti-tumour Effects of the Mtor Inhibitor Everolimus Against Melanoma

Intravenous Route to Choroidal Neovascularization by Macrophage-Disguised Nanocarriers for Mtor Modulation

Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles

Design, synthesis, and evaluation of antitumor activity in Pseudolaric acid B Azole derivatives: Novel and potent angiogenesis inhibitor via regulation of the PI3K/AKT and MAPK mediated HIF-1/VEGF signaling pathway

Abstract 723: Beyond Temsirolimus: Discovery of PKI-587 a Highly Efficacious Dual PI3K/mTOR Inhibitor

Combination of Molecule-Targeted Therapy and Photodynamic Therapy Using Nanoformulated Verteporfin for Effective Uveal Melanoma Treatment

Hybrid Inhibitors of Phosphatidylinositol 3-Kinase (PI3K) and the Mammalian Target of Rapamycin (mtor): Design, Synthesis, and Superior Antitumor Activity of Novel Wortmannin-Rapamycin Conjugates.